The global axial Spondyloarthritis management market garnered a market value of US$ 4.22 Billion in 2022 and is expected to accumulate a market value of US$ 7.3 Billion by registering a CAGR of 5.1% in the forecast period 2023 to 2033. Growth of the axial Spondyloarthritis management market can be attributed to escalating prevalence of axSpA and the growing need for efficient treatments. The market for axial Spondyloarthritis management registered a CAGR of 3.5% in the historical period 2018 to 2022
Axial Spondyloarthritis (axSpA) Management Market refers to the market for drugs, therapies, and medical devices used for the treatment and management of Axial Spondyloarthritis. Axial Spondyloarthritis is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, causing chronic pain and stiffness in the back and hips.
The management of Axial Spondyloarthritis includes a range of approaches, such as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and physical therapy. The market for Axial Spondyloarthritis Management is driven by the growing prevalence of the disease, rising healthcare expenditure, and increasing research and development activities by pharmaceutical companies to develop effective treatments for the condition.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.44 Billion |
| Anticipated Forecast Value (2033) | US$ 7.3 Billion |
| Projected Growth Rate (2023 to 2033) | 5.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Axial Spondyloarthritis management reflected a value of 3.5% during the historical period, 2018 to 2022.
the Axial Spondyloarthritis Management Market showed steady growth during this period. The market was primarily driven by the increasing prevalence of Axial Spondyloarthritis, which was expected to continue to rise due to factors such as changing lifestyle habits, an aging population, and genetic predisposition.
Moreover, the development and launch of new drugs and therapies for Axial Spondyloarthritis management also contributed to market growth. Biologic drugs such as tumor necrosis factor (TNF) inhibitors, Interleukin (IL)-17 inhibitors, and Janus kinase (JAK) inhibitors have shown promising results in clinical trials and have been approved for the treatment of Axial Spondyloarthritis.
Thus, the market for Axial Spondyloarthritis management is expected to register a CAGR of 5.1% in the forecast period 2023 to 2033.
Advances in technology and research along with increasing prevalence of Axial Spondyloarthritis driving market growth
The prevalence of Axial Spondyloarthritis is increasing globally, driven by factors such as changing lifestyle habits, an aging population, and genetic predisposition. As a result, the demand for effective management options for the condition is also growing, driving the growth of the Axial Spondyloarthritis Management Market.
Advances in technology and research have led to the development of new drugs and therapies for the management of Axial Spondyloarthritis. Biologic drugs, which are a newer class of drugs that target specific molecules involved in the inflammatory process, have shown promising results in clinical trials and have been approved for the treatment of Axial Spondyloarthritis.
Rising healthcare expenditure, particularly in developing countries, is driving the growth of the Axial Spondyloarthritis Management Market. Increased spending on healthcare infrastructure, research and development, and public health programs is expected to increase access to Axial Spondyloarthritis management options.
Several governments worldwide are taking initiatives to raise awareness about Axial Spondyloarthritis and its management. They are also promoting research and development activities to develop new treatments for the condition. These initiatives are expected to drive the growth of the Axial Spondyloarthritis Management Market.
Availability of treatments shaping the landscape for Axial Spondyloarthritis management market
Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDs such as ibuprofen and naproxen can help to reduce pain and inflammation associated with Axial Spondyloarthritis.
Disease-modifying anti-rheumatic drugs (DMARDs): DMARDs such as sulfasalazine and methotrexate can help to slow down the progression of the disease by reducing inflammation and preventing joint damage.
Biologic drugs: Biologic drugs such as tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and Janus kinase (JAK) inhibitors target specific molecules involved in the inflammatory process, reducing inflammation and relieving symptoms.
Physical therapy: Physical therapy can help to improve flexibility, strengthen muscles, and reduce pain and stiffness associated with Axial Spondyloarthritis.
Lifestyle changes: Lifestyle changes such as maintaining a healthy weight, quitting smoking, and getting regular exercise can also help to manage symptoms and improve overall health.
Principal Consultant
High treatment cost along with adverse effects of treatment derailing market growth
The cost of biologic drugs used in the management of Axial Spondyloarthritis is relatively high, making them less accessible to patients who cannot afford them. This can limit the market's growth and hinder the adoption of new treatments.
There is a lack of awareness about Axial Spondyloarthritis and its management among patients and healthcare professionals. This can delay diagnosis and treatment, leading to poor health outcomes. Biologic drugs used in the management of Axial Spondyloarthritis can cause adverse effects, such as infections, allergic reactions, and malignancies. This can limit the use of these drugs and affect patient outcomes.
Many of the biologic drugs used in the management of Axial Spondyloarthritis are under patent protection, limiting the availability of generic versions and leading to higher prices. As these patents expire, the market may become more competitive, affecting the profitability of companies.
Regulatory approval processes for new drugs and therapies can be lengthy and complex, leading to delays in the availability of new treatments for Axial Spondyloarthritis. Additionally, changing regulatory requirements can also affect the market's growth and profitability.
Physical therapy and lifestyle changes can be effective in managing Axial Spondyloarthritis symptoms. The availability of these alternative treatments can limit the market's growth and affect the adoption of new treatments.
Availability of effective treatment options favoring market growth of Axial Spondyloarthitis market
The North America Axial Spondyloarthritis Management Market is a significant segment of the global Axial Spondyloarthritis Management Market. It includes the United States and Canada, which are the largest markets for Axial Spondyloarthritis management in the region.
The North America Axial Spondyloarthritis Management Market is driven by several factors, including an increasing prevalence of the condition, a growing aging population, and a rising demand for effective management options. In addition, the region's advanced healthcare infrastructure, increasing healthcare expenditure, and favorable reimbursement policies are also contributing to market growth.
The market includes various treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologic drugs. Biologic drugs, which are a newer class of drugs that target specific molecules involved in the inflammatory process, are expected to drive the market's growth due to their high efficacy in managing the condition. Thus, North America is expected to possess 45% market share for Axial Spondyloarthritis management market in 2023.
Growing aging population along with favorable reimbursement policies bolstering market growth
The Europe Axial Spondyloarthritis Management Market is a significant segment of the global Axial Spondyloarthritis Management Market. It includes countries such as Germany, France, the United Kingdom, Spain, Italy, and others.
The prevalence of Axial Spondyloarthritis is increasing in Europe, which is driving the demand for effective management options. According to the European League Against Rheumatism (EULAR), the prevalence of Axial Spondyloarthritis in Europe is estimated to be between 0.2% and 1.4% of the population.
The aging population in Europe is driving the demand for effective management options for Axial Spondyloarthritis, as the condition is more common among older adults. Europe has a well-developed healthcare infrastructure, which is facilitating the diagnosis and management of Axial Spondyloarthritis.
Many European countries have favorable reimbursement policies for the management of Axial Spondyloarthritis, which is making treatment more accessible to patients. There is ongoing research and development in the field of Axial Spondyloarthritis, which is leading to the development of new treatment options and driving market growth. There are various initiatives in Europe aimed at raising awareness about Axial Spondyloarthritis among patients and healthcare professionals, which is driving early diagnosis and treatment. Thus, Europe is expected to hold 39% market share for Axial Spondyloarthritis management market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Access to specialists and surgeons boosting dependency on hospitals for Axial Spondyloarthritis management
Hospitals can provide effective treatment for Axial Spondyloarthritis, but it depends on various factors such as the severity of the condition, the experience and expertise of the healthcare providers, and the available resources and facilities.
Patients with severe Axial Spondyloarthritis may require hospitalization for intensive treatment, such as intravenous medications or surgery, while others may receive treatment on an outpatient basis. In both cases, hospitals can provide access to specialists, such as rheumatologists or orthopedic surgeons, who have extensive training and experience in managing the condition. Thus, hospitals are expected to possess 44% market share for Axial Spondyloarthritis management market in 2023.
Key players in the axial Spondyloarthritis management market are AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly and Company, Kyowa Kirin, Celgene, Inmagene Biopharmaceuticals
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.44 Billion |
| Market Value in 2033 | US$ 7.3 Billion |
| Growth Rate | CAGR of 5.1% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market value is estimated to be near US$ 4.44 billion in 2023.
Hospitals remain the preferred choice and could have fairly 44% of the total market share in 2023.
North America market to hold 45% market share in 2023.
The market in Europe is expected to acquire 39% of the global revenue in 2023.
Expensive cost of biologic drugs is the main challenge.
1. Executive Summary | Axial Spondyloarthritis Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Types
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Types, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Types, 2023 to 2033
5.3.1. Ankylosing Spondylitis Treatment
5.3.2. Non-Radiographic Axial Spondyloarthritis Treatment
5.4. Y-o-Y Growth Trend Analysis By Types, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Types, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
6.3.1. Non-steroidal anti-inflammatory drugs
6.3.2. Glucocorticoids
6.3.3. Anti-rheumatic drugs
6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospital
7.3.2. Clinics
7.3.3. Rehabilitation Centre
7.3.4. Academic Research Institutes
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Types
9.2.3. By Drug Class
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Types
9.3.3. By Drug Class
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Types
10.2.3. By Drug Class
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Types
10.3.3. By Drug Class
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Types
11.2.3. By Drug Class
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Types
11.3.3. By Drug Class
11.3.4. By End User
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Types
12.2.3. By Drug Class
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Types
12.3.3. By Drug Class
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Types
13.2.3. By Drug Class
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Types
13.3.3. By Drug Class
13.3.4. By End User
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Types
14.2.3. By Drug Class
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Types
14.3.3. By Drug Class
14.3.4. By End User
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Types
15.2.3. By Drug Class
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Types
15.3.3. By Drug Class
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Types
16.1.2.2. By Drug Class
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Types
16.2.2.2. By Drug Class
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Types
16.3.2.2. By Drug Class
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Types
16.4.2.2. By Drug Class
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Types
16.5.2.2. By Drug Class
16.5.2.3. By End User
16.6. U.K.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Types
16.6.2.2. By Drug Class
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Types
16.7.2.2. By Drug Class
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Types
16.8.2.2. By Drug Class
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Types
16.9.2.2. By Drug Class
16.9.2.3. By End User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Types
16.10.2.2. By Drug Class
16.10.2.3. By End User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Types
16.11.2.2. By Drug Class
16.11.2.3. By End User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Types
16.12.2.2. By Drug Class
16.12.2.3. By End User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Types
16.13.2.2. By Drug Class
16.13.2.3. By End User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Types
16.14.2.2. By Drug Class
16.14.2.3. By End User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Types
16.15.2.2. By Drug Class
16.15.2.3. By End User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Types
16.16.2.2. By Drug Class
16.16.2.3. By End User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Types
16.17.2.2. By Drug Class
16.17.2.3. By End User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Types
16.18.2.2. By Drug Class
16.18.2.3. By End User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Types
16.19.2.2. By Drug Class
16.19.2.3. By End User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Types
16.20.2.2. By Drug Class
16.20.2.3. By End User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Types
16.21.2.2. By Drug Class
16.21.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Types
17.3.3. By Drug Class
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. AbbVie
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Pfizer
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Amgen
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Janssen Biotech
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Pozen
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Iroko Pharmaceuticals
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Syntex Pharmaceuticals
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Horizon Pharma
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Eli Lilly and Company
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Kyowa Kirin
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Celgene
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Inmagene Biopharmaceuticals
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Axial Spondyloarthritis Management Market
